FDA Investigating Risk of T-cell Malignancy From CAR-T Cell Immunotherapies

After receiving reports of T-cell malignancies in patients who received treatment with BCMA- or CD19-directed autologous CAR-T cell immunotherapies, the agency has announced an investigation into the issue and is evaluating the need for regulatory action.
Source: Drug Industry Daily